ABSTRACT
Background Limited therapeutic options exist for coronavirus disease 2019 (COVID-19). COVID-19 convalescent plasma (CCP) is a potential therapeutic, but there is limited data for patients with moderate-to-severe disease.
Research Question What are outcomes associated with administration of CCP in patients with moderate-to-severe COVID-19 infection?
Study Design and Methods We conducted a propensity score-matched analysis of patients with moderate-to-severe COVID-19. The primary endpoints were in-hospital mortality. Secondary endpoints were number of days alive and ventilator-free at 30 days; length of hospital stay; and change in WHO scores from CCP administration (or index date) to discharge. Of 151 patients who received CCP, 132 had complete follow-up data. Patients were transfused after a median of 6 hospital days; thus, we investigated the effect of convalescent plasma before and after this timepoint with 77 early (within 6 days) and 55 late (after 6 days) recipients. Among 3,217 inpatients who did not receive CCP, 2,551 were available for matching.
Results Early CCP recipients, of whom 31 (40%) were on mechanical ventilation, had lower 14-day (15% vs 23%) and 30-day (38% vs 49%) mortality compared to a matched unexposed cohort, with nearly 50% lower likelihood of in-hospital mortality (HR 0.52, [95% CI 0.28-0.96]; P=0.036). Early plasma recipients had more days alive and ventilator-free at 30 days (+3.3 days, [95% CI 0.2 to 6.3 days]; P=0.04) and improved WHO scores at 7 days (−0.8, [95% CI: −1.2 to - 0.4]; P=0.0003) and hospital discharge (−0.9, [95% CI: −1.5 to −0.3]; P=0.004) compared to the matched unexposed cohort. No clinical differences were observed in late plasma recipients.
Interpretation Early administration of CCP improves outcomes in patients with moderate-to-severe COVID-19, while improvement was not observed with late CCP administration. The importance of timing of administration should be addressed in specifically designed trials.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
This was a medical record review; an observational study. It was not a clinical trial. As such it was not registered with clinicaltrials.gov
Funding Statement
This project has been funded in whole or in part with Federal funds from the US Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority under Contract No. 75A50120C00096. This publication was also made possible by the Yale University Diversity Initiative Faculty Excellence award (to MSD); the CTSA Grant Number UL1 TR000142 (to FL; YD) from the National Center for Advancing Translational Science (NCATS) and the National Institutes of Health; the Immunohematology/Transfusion Medicine Research Training Grant Number T32 HL007974 (to MLR) from the National Heart Lung and Blood Institute (NHLBI); the DeLuca Center for Innovation in Hematology Research at Yale Cancer Center and The Frederick A. Deluca Foundation (to SLB); the Bernard Forget Scholarship in the Section of Hematology and Yale Cancer Center (to SLB).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Yale University Institutional Review Board (HIC#: 2000027871) with an approved waiver of informed consent.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
All authors declare no conflicts of interest.
This project has been funded in whole or in part with Federal funds from the US Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority under Contract No. 75A50120C00096. This publication was also made possible by the Yale University Dean’s Diversity Initiative Faculty Excellence award (to MSD); the CTSA Grant Number UL1 TR000142 (to FL, YD) from the National Center for Advancing Translational Science (NCATS) and the National Institutes of Health; the Immunohematology/Transfusion Medicine Research Training Grant Number T32 HL007974 (to MLR) from the National Heart, Lung, and Blood Institute (NHLBI); the DeLuca Center for Innovation in Hematology Research at Yale Cancer Center and The Frederick A. Deluca Foundation (to SLB); the Bernard Forget Scholarship in the Section of Hematology and Yale Cancer Center (to SLB).
Data Availability
All data contained herein are available accordingly.
Abbreviations
- ALC
- Absolute lymphocyte count
- AA
- African American
- ALT
- Alanine transaminase
- AST
- aspartate aminotransferase
- BMI
- Body mass index
- CCI
- Charlson cormorbidity index COVID-19 Coronavirus disease 2019
- CCP
- COVID-19 convalescent plasma
- EAP
- Expanded Access Program
- ECMO
- Extracorporeal membrane oxygenation
- FDA
- Food and Drug Administration
- ICU
- Intensive care unit
- L
- Liters
- NT-PROBNP
- N-terminal-pro B-type natriuretic peptide
- O2
- Oxygen
- SPO2
- Oxygen saturation
- RECOVERY
- Randomized evaluation of COVID-19 therapy SARS-CoV-2 severe acute respiratory syndrome coronavirus 2 WHO World Health Organization
- YNHHS
- Yale-New Haven Health System
